312 related articles for article (PubMed ID: 31623592)
1. Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer.
Advani SM; Advani PS; Brown DW; DeSantis SM; Korphaisarn K; VonVille HM; Bressler J; Lopez DS; Davis JS; Daniel CR; Sarshekeh AM; Braithwaite D; Swartz MD; Kopetz S
BMC Cancer; 2019 Oct; 19(1):964. PubMed ID: 31623592
[TBL] [Abstract][Full Text] [Related]
2. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer.
Karpinski P; Ramsey D; Grzebieniak Z; Sasiadek MM; Blin N
Mol Cancer Res; 2008 Apr; 6(4):585-91. PubMed ID: 18403637
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer.
Advani SM; Swartz MD; Loree J; Davis JS; Sarsashek AM; Lam M; Lee MS; Bressler J; Lopez DS; Daniel CR; Morris V; Shureqi I; Kee B; Dasari A; Vilar E; Overman M; Hamilton S; Maru D; Braithwaite D; Kopetz S
Clin Colorectal Cancer; 2021 Jun; 20(2):137-147.e1. PubMed ID: 33229221
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling.
Hinoue T; Weisenberger DJ; Pan F; Campan M; Kim M; Young J; Whitehall VL; Leggett BA; Laird PW
PLoS One; 2009 Dec; 4(12):e8357. PubMed ID: 20027224
[TBL] [Abstract][Full Text] [Related]
5. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer.
Ogino S; Kawasaki T; Kirkner GJ; Suemoto Y; Meyerhardt JA; Fuchs CS
Gut; 2007 Nov; 56(11):1564-71. PubMed ID: 17339237
[TBL] [Abstract][Full Text] [Related]
6. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
[TBL] [Abstract][Full Text] [Related]
7. CpG island methylator phenotype and prognosis of colorectal cancer in Northeast China.
Li X; Hu F; Wang Y; Yao X; Zhang Z; Wang F; Sun G; Cui BB; Dong X; Zhao Y
Biomed Res Int; 2014; 2014():236361. PubMed ID: 25243122
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis.
Juo YY; Johnston FM; Zhang DY; Juo HH; Wang H; Pappou EP; Yu T; Easwaran H; Baylin S; van Engeland M; Ahuja N
Ann Oncol; 2014 Dec; 25(12):2314-2327. PubMed ID: 24718889
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of CpG island methylator phenotype among hepatocellular carcinoma patients: A systematic review and meta-analysis.
Wang Q; Wang G; Liu C; He X
Int J Surg; 2018 Jun; 54(Pt A):92-99. PubMed ID: 29698791
[TBL] [Abstract][Full Text] [Related]
10. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
Kim JH; Bae JM; Cho NY; Kang GH
Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
[TBL] [Abstract][Full Text] [Related]
11. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.
Goel A; Nagasaka T; Arnold CN; Inoue T; Hamilton C; Niedzwiecki D; Compton C; Mayer RJ; Goldberg R; Bertagnolli MM; Boland CR
Gastroenterology; 2007 Jan; 132(1):127-38. PubMed ID: 17087942
[TBL] [Abstract][Full Text] [Related]
12. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype.
Yamamoto E; Suzuki H; Yamano HO; Maruyama R; Nojima M; Kamimae S; Sawada T; Ashida M; Yoshikawa K; Kimura T; Takagi R; Harada T; Suzuki R; Sato A; Kai M; Sasaki Y; Tokino T; Sugai T; Imai K; Shinomura Y; Toyota M
Am J Pathol; 2012 Nov; 181(5):1847-61. PubMed ID: 22995252
[TBL] [Abstract][Full Text] [Related]
13. Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review.
Jia M; Gao X; Zhang Y; Hoffmeister M; Brenner H
Clin Epigenetics; 2016; 8():25. PubMed ID: 26941852
[TBL] [Abstract][Full Text] [Related]
14. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma.
Ogino S; Odze RD; Kawasaki T; Brahmandam M; Kirkner GJ; Laird PW; Loda M; Fuchs CS
Am J Surg Pathol; 2006 Sep; 30(9):1175-83. PubMed ID: 16931963
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic insights into colorectal cancer: comprehensive genome-wide DNA methylation profiling of 294 patients in Korea.
Joe S; Kim J; Lee JY; Jeon J; Byeon I; Han SW; Ryoo SB; Park KJ; Song SH; Cho S; Shim H; Bao Khanh Chu H; Kang J; Lee HS; Kim D; Kim YJ; Kim TY; Kim SY
BMB Rep; 2023 Oct; 56(10):563-568. PubMed ID: 37574809
[TBL] [Abstract][Full Text] [Related]
16. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.
Dahlin AM; Palmqvist R; Henriksson ML; Jacobsson M; Eklöf V; Rutegård J; Oberg A; Van Guelpen BR
Clin Cancer Res; 2010 Mar; 16(6):1845-55. PubMed ID: 20197478
[TBL] [Abstract][Full Text] [Related]
17. CpG island methylator phenotype is an independent predictor of survival after curative resection for colorectal cancer: A prospective cohort study.
Kim CH; Huh JW; Kim HR; Kim YJ
J Gastroenterol Hepatol; 2017 Aug; 32(8):1469-1474. PubMed ID: 28087988
[TBL] [Abstract][Full Text] [Related]
18. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
[TBL] [Abstract][Full Text] [Related]
19. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype.
Toyota M; Ohe-Toyota M; Ahuja N; Issa JP
Proc Natl Acad Sci U S A; 2000 Jan; 97(2):710-5. PubMed ID: 10639144
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
Overman MJ; Adam L; Raghav K; Wang J; Kee B; Fogelman D; Eng C; Vilar E; Shroff R; Dasari A; Wolff R; Morris J; Karunasena E; Pisanic TR; Azad N; Kopetz S
Ann Oncol; 2018 Jan; 29(1):139-144. PubMed ID: 29069279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
